Page 1 | Search Results | Blood Advances | American Society of Hematology

1-20 of 97

Sort by

Sort Order Select

Journal Articles

Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA study

Blood Adv (2021) 5 (19): 3862–3872.

https://doi.org/10.1182/bloodadvances.2021004778

Published: 2021

Includes: Supplemental data

Journal Articles

Optimizing outcomes in primary mediastinal B-cell lymphoma: is R-CHOP enough?

Michael R. Cook, Kieron Dunleavy

Blood Adv (2021) 5 (19): 3873–3875.

https://doi.org/10.1182/bloodadvances.2021005190

Published: 2021

Journal Articles

The selection of variable regions affects effector mechanisms of IgA antibodies against CD20

Mitchell Evers, Thies Rösner, Anna Dünkel, J. H. Marco Jansen, Niklas Baumann, Toine ten Broeke, Maaike Nederend, Klara Eichholz, Katja Klausz, Karli Reiding, Denis M. Schewe, Christian Kellner, Matthias Peipp, Jeanette H. W. Leusen, Thomas Valerius

Blood Adv (2021) 5 (19): 3807–3820.

https://doi.org/10.1182/bloodadvances.2021004598

Published: 2021

Includes: Supplemental data

Journal Articles

Fatal late-onset CAR T-cell–mediated encephalitis after axicabtagene-ciloleucel in a patient with large B-cell lymphoma

Susanne Jung, Jochen Greiner, Stephanie von Harsdorf, Pavle Popovic, Roland Moll, Jens Schittenhelm, Kosmas Kandilaris, Volker Daniel, Alexander Kunz, Michael Schmitt, Peter Dreger

Blood Adv (2021) 5 (19): 3789–3793.

https://doi.org/10.1182/bloodadvances.2021004889

Published: 2021

Includes: Supplemental data

Journal Articles

Real-world outcomes of axicabtagene ciloleucel in adult patients with primary mediastinal B-cell lymphoma

Jennifer L. Crombie, Loretta J. Nastoupil, Robert Redd, Kevin Tang, Geoffrey Shouse, Alex F. Herrera, Victor A. Chow, Mazyar Shadman, Omar Castaneda Puglianini, Anna Saucier, Caron A. Jacobson, Philippe Armand, Gary Simmons

Blood Adv (2021) 5 (18): 3563–3567.

https://doi.org/10.1182/bloodadvances.2021004880

Published: 2021

Journal Articles

Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma

Blood Adv (2021) 5 (15): 2935–2944.

https://doi.org/10.1182/bloodadvances.2020003985

Published: 2021

Includes: Supplemental data

Journal Articles

CRP and ferritin in addition to the EASIX score predict CAR-T–related toxicity

Blood Adv (2021) 5 (14): 2799–2806.

https://doi.org/10.1182/bloodadvances.2021004575

Published: 2021

Includes: Supplemental data

Journal Articles

Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance)

Blood Adv (2021) 5 (13): 2775–2787.

https://doi.org/10.1182/bloodadvances.2021004233

Published: 2021

Includes: Supplemental data

Journal Articles

Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas

Blood Adv (2021) 5 (13): 2707–2716.

https://doi.org/10.1182/bloodadvances.2020004155

Published: 2021

Includes: Supplemental data

Journal Articles

Toxicities of high-dose chemotherapy and autologous hematopoietic cell transplantation in older patients with lymphoma

Parastoo B. Dahi, Jasme Lee, Sean M. Devlin, Josel Ruiz, Molly Maloy, Carlos Rondon-Clavo, Erica Petrlik, Roni Tamari, Gunjan Shah, Michael Scordo, Matthew J. Matasar, Paul A. Hamlin, Esperanza Papadopoulos, Ann A. Jakubowski, Miguel-Angel Perales, Craig H. Moskowitz, Craig S. Sauter, Sergio A. Giralt

Blood Adv (2021) 5 (12): 2608–2618.

https://doi.org/10.1182/bloodadvances.2020004167

Published: 2021

Includes: Supplemental data

Journal Articles

Qi S-N, Yang Y, Song Y-Q, et al. First-line non–anthracycline-based chemotherapy for extranodal nasal-type NK/T-cell lymphoma: a retrospective analysis from the CLCG. Blood Adv. 2020;4(13):3141-3153.

Blood Adv (2021) 5 (12): 2576.

https://doi.org/10.1182/bloodadvances.2021005072

Published: 2021

Journal Articles

Liquid biopsy in extranodal NK/T-cell lymphoma: a prospective analysis of cell-free DNA genotyping and monitoring

Fei Qi, Zheng Cao, Bo Chen, Yue Chai, Jing Lin, Junyi Ye, Yuce Wei, Hao Liu, Han Han-Zhang, Xinru Mao, Xiaoli Feng, Mei Dong

Blood Adv (2021) 5 (11): 2505–2514.

https://doi.org/10.1182/bloodadvances.2020001637

Published: 2021

Includes: Supplemental data

Journal Articles

Study of the antilymphoma activity of pracinostat reveals different sensitivities of DLBCL cells to HDAC inhibitors

Afua Adjeiwaa Mensah, Filippo Spriano, Giulio Sartori, Valdemar Priebe, Luciano Cascione, Eugenio Gaudio, Chiara Tarantelli, Elisa Civanelli, Luca Aresu, Andrea Rinaldi, Giovanna Damia, Emanuela Lovati, Emanuele Zucca, Anastasios Stathis, Claudio Pietra, Francesco Bertoni

Blood Adv (2021) 5 (10): 2467–2480.

https://doi.org/10.1182/bloodadvances.2020003566

Published: 2021

Includes: Supplemental data

Journal Articles

Low-cost transcriptional diagnostic to accurately categorize lymphomas in low- and middle-income countries

Fabiola Valvert, Oscar Silva, Elizabeth Solórzano-Ortiz, Maneka Puligandla, Marcos Mauricio Siliézar Tala, Timothy Guyon, Samuel L. Dixon, Nelly López, Francisco López, César Camilo Carías Alvarado, Robert Terbrueggen, Kristen E. Stevenson, Yasodha Natkunam, David M. Weinstock, Edward L. Briercheck

Blood Adv (2021) 5 (10): 2447–2455.

https://doi.org/10.1182/bloodadvances.2021004347

Published: 2021

Includes: Supplemental data

Journal Articles

Treating lymphoma is now a bit EZ-er

Ryan D. Morin, Sarah E. Arthur, Sarit Assouline

Blood Adv (2021) 5 (8): 2256–2263.

https://doi.org/10.1182/bloodadvances.2020002773

Published: 2021

Journal Articles

Effect of lisocabtagene maraleucel on HRQoL and symptom severity in relapsed/refractory large B-cell lymphoma

Donald L. Patrick, Annette Powers, Monika Parisi Jun, Yeonhee Kim, Jacob Garcia, Christine Dehner, David G. Maloney

Blood Adv (2021) 5 (8): 2245–2255.

https://doi.org/10.1182/bloodadvances.2020003503

Published: 2021

Includes: Supplemental data

Journal Articles

Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs

Lucia Masarova, Courtney D. DiNardo, Prithviraj Bose, Naveen Pemmaraju, Naval G. Daver, Tapan M. Kadia, Helen T. Chifotides, Lingsha Zhou, Gautam Borthakur, Zeev Estrov, Marina Konopleva, Srdan Verstovsek

Blood Adv (2021) 5 (8): 2156–2164.

https://doi.org/10.1182/bloodadvances.2020003934

Published: 2021

Includes: Supplemental data

Journal Articles

Involved-site radiotherapy for Helicobacter pylori –independent gastric MALT lymphoma: 26 years of experience with 178 patients

Joachim Yahalom, Amy J. Xu, Ariela Noy, Stephanie Lobaugh, Monica Chelius, Karen Chau, Carol Portlock, Carla Hajj, Brandon S. Imber, David J. Straus, Craig H. Moskowitz, Morton Coleman, Andrew D. Zelenetz, Zhigang Zhang, Ahmet Dogan

Blood Adv (2021) 5 (7): 1830–1836.

https://doi.org/10.1182/bloodadvances.2020003992

Published: 2021

Journal Articles

Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel–treated patients in the TRANSCEND NHL 001 trial

Jeremy S. Abramson, Tanya Siddiqi, Jacob Garcia, Christine Dehner, Yeonhee Kim, Andy Nguyen, Sophie Snyder, November McGarvey, Matthew Gitlin, Corey Pelletier, Monika P. Jun

Blood Adv (2021) 5 (6): 1695–1705.

https://doi.org/10.1182/bloodadvances.2020003531

Published: 2021

Journal Articles

Unmarried or less-educated patients with mantle cell lymphoma are less likely to undergo a transplant, leading to lower survival

Ingrid Glimelius, Karin E. Smedby, Alexandra Albertsson-Lindblad, Michael J. Crowther, Sandra Eloranta, Mats Jerkeman, Caroline E. Weibull

Blood Adv (2021) 5 (6): 1638–1647.

https://doi.org/10.1182/bloodadvances.2020003645

Published: 2021

Includes: Supplemental data

NARROW

Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA study

Optimizing outcomes in primary mediastinal B-cell lymphoma: is R-CHOP enough?

The selection of variable regions affects effector mechanisms of IgA antibodies against CD20

Fatal late-onset CAR T-cell–mediated encephalitis after axicabtagene-ciloleucel in a patient with large B-cell lymphoma

Real-world outcomes of axicabtagene ciloleucel in adult patients with primary mediastinal B-cell lymphoma

Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma

CRP and ferritin in addition to the EASIX score predict CAR-T–related toxicity

Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance)

Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas

Toxicities of high-dose chemotherapy and autologous hematopoietic cell transplantation in older patients with lymphoma

Qi S-N, Yang Y, Song Y-Q, et al. First-line non–anthracycline-based chemotherapy for extranodal nasal-type NK/T-cell lymphoma: a retrospective analysis from the CLCG. Blood Adv. 2020;4(13):3141-3153.

Liquid biopsy in extranodal NK/T-cell lymphoma: a prospective analysis of cell-free DNA genotyping and monitoring

Study of the antilymphoma activity of pracinostat reveals different sensitivities of DLBCL cells to HDAC inhibitors

Low-cost transcriptional diagnostic to accurately categorize lymphomas in low- and middle-income countries

Treating lymphoma is now a bit EZ-er

Effect of lisocabtagene maraleucel on HRQoL and symptom severity in relapsed/refractory large B-cell lymphoma

Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs

Involved-site radiotherapy for Helicobacter pylori –independent gastric MALT lymphoma: 26 years of experience with 178 patients

Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel–treated patients in the TRANSCEND NHL 001 trial

Unmarried or less-educated patients with mantle cell lymphoma are less likely to undergo a transplant, leading to lower survival

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only